Products with Wound-healing bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4876 | Lucidone |
| 1. Lucidone has anti-inflammatory activity, the activity might be caused by the inhibition of iNOS and COX-2 expressions through downregulation of NF-kappaB and AP-1 binding. 2. Lucidone has hepatoprotective effect, it-mediated up-regulation of phase-II enzymes and HO-1 via Nrf-2 signaling pathway may provide a pivotal mechanism for its hepatoprotective action. 3. Lucidone may possess antioxidant and anti-inflammatory properties and may be useful for the prevention of free radical-induced skin damage. 4. Dietary intake of lucidone alleviates high fat diet-induced obesity in C57BL/6 mice and reveals the potential of lucidone as a nutraceutical to prevent obesity and consequent metabolic disorders. 5. Lucidone accelerates wound healing through the cooperation of keratinocyte/fibroblast/ ndothelial cell growth and migration and macrophage inflammation via PI3K/AKT, Wnt/β-catenin and NF-κB signaling cascade activation. 6. Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction, it could be a potential lead or supplement for the development of new anti-HCV agent in the future. | |
| BCN5943 | Glycyrrhizic acid ammonium salt |
| Glycyrrhizic acid ammonium salt has wound healing activity. | |
| BCN5972 | (+)-Taxifolin |
| (+)-Taxifolin is an inhibitor of aggregation of the 42-residue amyloid β-protein, it has preventive effects against Alzheimer's disease-like pathogenesis in vivo. It is also a weak inhibitor of cytochrome b5 reduction (IC50=9.8μM). | |
| BCN6219 | Sweroside |
| Sweroside possesses wound healing, cytoprotective, skin-whitening , anti-osteoporotic , and hepatoprotective effect. It can inhibit potent melanogenesis in melan-a cells at 300uM without cytotoxicity, also decreases tyrosinase, tyrosinase-related protein-1 (TRP-1) and TRP-2 protein production in melan a cells. It also shows insulin-mimicking effects on the regulation of Pck1 expression. | |
| BCN6434 | Notoginsenoside Ft1 |
| 1. Notoginsenoside Ft1 may accelerate diabetic wound healing by orchestrating multiple processes, including promoting fibroblast proliferation, enhancing angiogenesis, and attenuating inflammatory response, which provided a great potential application of it in clinics for patients with diabetic foot ulcers. 2. Notoginsenoside Ft1 can arrest the proliferation and elicited the apoptosis of SH-SY5Y cells possibly via p38 MAPK and ERK1/2 pathways, which indicates the potential therapeutic effect of it on human neuroblastoma. 3. Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. 4. Notoginsenoside Ft1 can enhance platelet aggregation by activating a signalling network mediated through P2Y₁₂ receptors. 5. Notoginsenoside Ft1 is a novel stimulator of angiogenesis, it stimulates angiogenesis via HIF-1α-mediated VEGF expression, with PI3K/AKT and Raf/MEK/ERK signaling cascades concurrently participating in the process. | |
